Home › Cancer (all types) › NCT07280715

Investigating Real-Time Immunotherapy Symptoms Study

Digital Remote Patient Monitoring and Triage During Cancer Immunotherapy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* receiving immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for melanoma;
* age 18 years or older;
* ability to read and write in English;
* owns and uses a smartphone capable of running study applications

Exclusion Criteria:

* under 18 years old; and
* unable to read and write in English

About the study

The goal of this study is to evaluate the feasibility of using information from wearable devices and self-reported symptoms to remotely monitor patients during immunotherapy. The main questions it aims to answer are:

* Is the digital remote patient monitoring tool feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment?

Participants will:

* Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * As feasible: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

If participant is randomly assigned to the intervention group, they will also:

* Complete weekly symptom ratings via digital remote patient monitoring tool * Wear a Fitbit activity tracker as feasible for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study.

What is being tested

• Digital remote monitoring intervention (behavioral)
• Usual Care (other)

Sponsor: University of Pittsburgh · Participants: 40 · Started: Jun 17, 2026

Contact the study team

• Carissa A Low · Phone: 412-623-5973

Official record on ClinicalTrials.gov — NCT07280715

Locations in the U.S.

Conditions

• Cancer (all types)
• Melanoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.